Sangamo Therapeutics Income Statement (2010-2025) | SGMO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	26.28M	27.87M	28.56M		28.23M	29.38M	26.46M	27.23M	157.96M	6.83M	9.40M	2.04M	0.48M	0.36M	49.41M	6.50M	6.44M	18.31M	0.58M	14.23M
Operating items
Research & Development (Quarter)	56.43M	60.09M	62.50M	51.80M	58.58M	60.02M	65.12M	66.18M	63.22M	63.05M	57.09M	50.71M	35.89M	24.22M	27.73M	23.68M	26.01M	27.08M	28.14M	31.44M
Selling, General & Administrative (Quarter)	16.15M	16.49M	14.50M	16.08M	14.91M	15.09M	16.24M	16.44M	18.14M	16.01M	13.92M	13.10M	11.77M	12.04M	11.05M	9.87M	10.06M	9.08M	7.99M	7.76M
Other Operating Expenses (Quarter)									58.57M	51.35M	44.80M	0.30M	4.35M	1.17M						13.23M
Operating Expenses (Quarter)	72.58M	76.57M	77.00M	67.89M	73.49M	75.11M	81.35M	82.62M	139.92M	130.41M	115.81M	64.10M	52.01M	37.44M	38.78M	33.54M	36.06M	36.16M	36.13M	52.43M
Operating Income (Quarter)	-46.30M	-48.70M	-48.44M	-39.90M	-45.26M	-45.73M	-54.89M	-55.39M	18.03M	-123.57M	-106.41M	-62.06M	-51.53M	-37.08M	10.63M	-25.99M	-29.63M	-17.86M	-35.55M	-38.20M
EBIT (Quarter)	-46.30M	-48.70M	-48.44M	-39.90M	-45.26M	-45.73M	-54.89M	-55.39M	18.03M	-123.57M	-106.41M	-62.06M	-51.53M	-37.08M	10.63M	-25.99M	-29.63M	-17.86M	-35.55M	-38.20M
Non-operating items
Interest & Investment Income (Quarter)	0.62M	1.55M	0.83M	2.34M	1.34M	2.64M	1.77M	3.68M	3.29M	2.80M	3.52M	1.49M	0.45M	0.42M	0.35M	0.30M	0.31M	0.39M	0.35M	0.25M
Other Non Operating Income (Quarter)													2.08M	0.61M	-0.22M	1.87M	-1.16M	-2.49M	0.11M	-0.02M
Non Operating Income (Quarter)													2.08M	0.61M	-0.22M	1.87M	-1.16M	-2.49M	0.11M	-0.02M
Net income details
EBT (Quarter)	-45.68M	-47.15M	-47.60M	-37.56M	-43.92M	-43.09M	-53.12M	-51.71M	21.33M	-120.77M	-102.89M	-60.57M	-48.99M	-36.05M	10.76M	-23.82M	-30.48M	-19.96M	-35.09M	-37.97M
Tax Provisions (Quarter)	0.26M	0.02M	0.10M	-0.07M	0.10M	0.08M	0.03M	0.26M	0.19M	-6.26M	1.27M	-0.27M	0.10M	0.07M	0.09M	-0.43M	0.12M	0.03M	-0.16M	-0.55M
Profit After Tax (Quarter)	-45.93M	-47.17M	-47.69M	-37.50M	-43.98M	-43.17M	-53.16M	-51.97M	21.13M	-114.51M	-104.16M	-60.30M	-49.09M	-36.13M	10.67M	-23.40M	-30.60M	-19.99M	-34.93M	-37.42M
Income from Non-Controlling Interests (Quarter)	-0.01M	-0.01M
Income from Continuing Operations (Quarter)	-45.94M	-47.17M	-47.70M	-37.50M	-44.02M	-43.17M	-53.16M	-51.97M	21.13M	-114.51M	-104.16M	-60.30M	-49.09M	-36.13M	10.67M	-23.40M	-30.60M	-19.99M	-34.93M	-37.42M
Consolidated Net Income (Quarter)	-45.94M	-47.17M	-47.70M	-37.50M	-44.02M	-43.17M	-53.16M	-51.97M	21.13M	-114.51M	-104.16M	-60.30M	-49.09M	-36.13M	10.67M	-23.40M	-30.60M	-19.99M	-34.93M	-37.42M
Income towards Parent Company (Quarter)	-45.94M	-47.17M	-47.70M	-37.50M	-44.02M	-43.17M	-53.16M	-51.97M	21.13M	-114.51M	-104.16M	-60.30M	-49.09M	-36.13M	10.67M	-23.40M	-30.60M	-19.99M	-34.93M	-37.42M
Preferred Dividend Payments (Quarter)															1.29M
Net Income towards Common Stockholders (Quarter)	-45.94M	-47.17M	-47.69M	-37.50M	-44.02M	-43.17M	-53.16M	-51.97M	21.13M	-114.51M	-104.16M	-60.30M	-49.09M	-36.13M	9.38M	-23.40M	-30.60M	-19.99M	-34.93M	-37.42M
Additional items
EPS (Basic) (Quarter)	-0.32	-0.33	-0.33	-0.25	-0.30	-0.29	-0.34	-0.32	0.13	-0.66	-0.59	-0.34	-0.27	-0.18	0.05	-0.12	-0.14	-0.08	-0.11	-0.11
EPS (Weighted Average and Diluted) (Quarter)	-0.32	-0.33	-0.33	-0.25	-0.30	-0.29	-0.34	-0.32	0.12	-0.66	-0.59	-0.34	-0.27	-0.18	0.04	-0.12	-0.14	-0.08	-0.11	-0.11
Shares Outstanding (Weighted Average) (Quarter)	143.11M	143.98M	144.17M	144.57M	146.22M	147.19M	158.04M	154.34M	168.53M	174.32M	177.17M	174.44M	180.34M	203.90M	208.34M	201.70M	220.27M	257.00M	260.80M	280.19M
Shares Outstanding (Diluted Average) (Quarter)	143.11M	143.55M	144.17M	144.57M	146.22M	147.19M	158.04M	154.34M	169.18M	171.44M	177.17M	174.44M	180.30M	203.95M	214.32M	201.70M	220.30M	256.95M	260.80M	280.19M
EBITDA (Quarter)	-46.30M	-48.70M	-48.44M	-39.90M	-45.26M	-45.73M	-54.89M	-55.39M	18.03M	-123.57M	-106.41M	-62.06M	-51.53M	-37.08M	10.63M	-25.99M	-29.63M	-17.86M	-35.55M	-38.20M
Tax Rate (Quarter)	-0.57%	-0.05%	-0.21%	0.18%	-0.23%	-0.19%	-0.06%	-0.50%	0.91%	5.19%	-1.23%	0.45%	-0.20%	-0.21%	0.82%	1.79%	-0.39%	-0.14%	0.46%	1.46%

Research Tools

Sangamo Therapeutics Income Statement (2010-2025) | SGMO

Create an account

Sign In

Reset Password